A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma

• Egile Nagusiak: Takuji Okusaka (Egilea), Manabu Morimoto (Egilea), Yuichiro Eguchi (Egilea), Shinichiro Nakamura (Egilea), Shuichi Iino (Egilea), Rie Kageyama (Egilea)
• Formatua: Liburua
• Argitaratua: Adis, Springer Healthcare, 2023-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background and Objective For patients with advanced hepatocellular carcinoma (HCC), the standard of care for many years has been sorafenib. Preliminary data have suggested that the combination of the NAD(P)H:quinone oxidoreductase 1 bioactivatable agent napabucasin plus sorafenib may improv...